Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on September 25, 2006

Circulation. 2006
Published online before print September 25, 2006, doi: 10.1161/CIRCULATIONAHA.106.633206
A more recent version of this article appeared on October 3, 2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
114/14/1476    most recent
CIRCULATIONAHA.106.633206v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, J.-P.
Right arrow Articles by Kronenberg, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, J.-P.
Right arrow Articles by Kronenberg, F.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Epidemiology
Right arrow Genetics of cardiovascular disease
Right arrow Pathophysiology
Right arrow Risk Factors

Submitted on April 17, 2006
Revised on July 20, 2006
Accepted on July 25, 2006

Association Between the UGT1A1*28 Allele, Bilirubin Levels, and Coronary Heart Disease in the Framingham Heart Study

Jing-Ping Lin MD, PhD*, Christopher J. O’Donnell MD, MPH, Johannes P. Schwaiger MD, L. Adrienne Cupples PhD, Arno Lingenhel PhD, Steven C. Hunt PhD, Song Yang PhD, and Florian Kronenberg MD

From the Office of Biostatistics Research (J.-P.L., S.Y.) and Framingham Heart Study (C.J.O.), Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md; Division of Genetic Epidemiology/Department of Medical Genetics, Molecular and Clinical Pharmacology (J.P.S., A.L., F.K.), Innsbruck Medical University, Innsbruck, Austria; Department of Biostatistics (L.A.C.), Boston University School of Public Health, Boston, Mass; and Department of Internal Medicine (S.C.H.), University of Utah, Salt Lake City, Utah.

* To whom correspondence should be addressed. E-mail: linj{at}nhlbi.nih.gov.

Background--Bilirubin is an antioxidant that suppresses lipid oxidation and retards atherosclerosis formation. An inverse association between serum bilirubin and coronary heart disease has been reported. Linkage studies have identified a major locus at the chromosome 2q telomere that affects bilirubin concentrations. A candidate gene in the linkage region encodes hepatic bilirubin uridine diphosphate-glucuronosyltransferase (UGT1A1). The insertion of a TA in the TATAA box of the gene, an allele designated UGT1A1*28, decreases gene transcription. Individuals homozygous for UGT1A1*28 (genotype 7/7) have increased serum bilirubin levels compared with carriers of the 6 allele. To date, no significant association between UGT1A1*28 and cardiovascular disease (CVD) events has been reported. We performed an association study in the Framingham Heart Study population to investigate whether UGT1A1*28 is associated with the risk of CVD events.

Methods and Results--The study population included 1780 unrelated individuals from the Offspring cohort (49% males, mean age 36 years at entry) who had been followed up for 24 years. Individuals with genotype 7/7 had significantly higher bilirubin levels (mean±SD 1.14±0.44 mg/dL) than those with genotypes 6/6 and 6/7 (mean±SD 0.69±0.27 mg/dL, P<0.01). Using the Cox proportional hazards model, we found significant associations between the UGT1A1*28 allele and decreased risk of CVD. Individuals with genotype 7/7 (population frequency of 11%) had approximately one third the risk for CVD and coronary heart disease as carriers of the 6 allele, which resulted in a hazard ratio (95% confidence interval) of 0.36 (0.18 to 0.74) and 0.30 (0.12 to 0.74), respectively.

Conclusions--Homozygote UGT1A1*28 allele carriers with higher serum bilirubin concentrations exhibit a strong association with lower risk of CVD.


Key words: cardiovascular diseases • genetics • genes • atherosclerosis • enzymes • epidemiology • survival




This article has been cited by other articles:


Home page
Clin. Chem.Home page
B. Rantner, B. Kollerits, M. Anderwald-Stadler, P. Klein-Weigel, I. Gruber, A. Gehringer, M. Haak, M. Schnapka-Kopf, G. Fraedrich, and F. Kronenberg
Association between the UGT1A1 TA-Repeat Polymorphism and Bilirubin Concentration in Patients with Intermittent Claudication: Results from the CAVASIC Study
Clin. Chem., May 1, 2008; 54(5): 851 - 857.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. S. Perlstein, R. L. Pande, J. A. Beckman, and M. A. Creager
Serum Total Bilirubin Level and Prevalent Lower-Extremity Peripheral Arterial Disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004
Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 166 - 172.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A. L. Hong, D. Huo, H.-J. Kim, Q. Niu, D. L. Fackenthal, S. A. Cummings, E. M. John, D. W. West, A. S. Whittemore, S. Das, et al.
UDP-Glucuronosyltransferase 1A1 Gene Polymorphisms and Total Bilirubin Levels in an Ethnically Diverse Cohort of Women
Drug Metab. Dispos., August 1, 2007; 35(8): 1254 - 1261.
[Abstract] [Full Text] [PDF]